Mirtazapine Clearance
No, mirtazapine is NOT primarily cleared by the kidneys—it is predominantly metabolized by the liver, with approximately 75% eliminated via urine as metabolites and only up to 4% excreted unchanged in urine. 1
Primary Elimination Pathway
Mirtazapine undergoes extensive hepatic metabolism through demethylation and hydroxylation, primarily mediated by CYP2D6, CYP1A2, and CYP3A4 enzymes, followed by glucuronide conjugation 1, 2. The drug is then eliminated as metabolites: approximately 75% via urine and 15% via feces 1, 2.
Clinical Implications for Renal Impairment
While mirtazapine is not renally cleared in its active form, renal impairment does affect drug clearance due to reduced elimination of metabolites:
- Moderate renal impairment (GFR 11-39 mL/min/1.73 m²): Total body clearance reduced by approximately 30% 1
- Severe renal impairment (GFR <10 mL/min/1.73 m²): Clearance reduced by approximately 50% 1
Dosage adjustments are necessary for patients with moderate to severe renal impairment 1. The FDA label explicitly states that mirtazapine is "substantially excreted by the kidney (75%)" as metabolites, and patients with impaired renal function have greater risk of decreased clearance 1.
Contrast with Hepatic Impairment
Hepatic impairment causes approximately 30% decrease in oral clearance 1, which is comparable to moderate renal impairment but less severe than the 50% reduction seen in severe renal disease.
Key Clinical Pitfall
Do not assume mirtazapine is safe at standard doses in renal failure simply because it is hepatically metabolized. The accumulation of metabolites in renal impairment leads to increased parent drug exposure, requiring dose reduction and close monitoring for adverse effects including excessive sedation, confusion, and orthostatic hypotension—particularly problematic in elderly patients who often have concurrent renal dysfunction 1.